Antigen News and Research

RSS

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

Altravax, Inc. announced today that it has been awarded two SBIR grants totaling $1.2 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1.

6 Oct 2010

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Celldex Therapeutics, Inc. today announced that the Company presented initial clinical data on CDX-1401 at the 25th Annual Meeting of the International Society of Biological Therapy of Cancer (iSBTc) in Washington, DC. CDX-1401 is a novel antibody-based targeted cancer vaccine candidate being evaluated as a treatment for patients with melanoma and other cancers that are known to express the tumor antigen NY-ESO-1.

5 Oct 2010

FDA awards $2.9 million to support tuberculosis research projects

The U.S. Food and Drug Administration today announced the award of $2.9 million to support six research projects that will help with the diagnosis, treatment, and prevention of tuberculosis (TB).

5 Oct 2010

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).

4 Oct 2010

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial.

1 Oct 2010

Healthy respect for flu this season

Flu season officially begins Friday, Oct. 1, and unlike last year's season when shortages lead to rationing, there will be plenty of vaccine on hand for everyone who wants a flu shot.

1 Oct 2010

Discovery suggest a new direction for designing vaccines for rare HIV infection

New discoveries about the immune defenses of rare HIV patients who produce antibodies that prevent infection suggest a novel direction for designing new vaccines. Researchers at Rockefeller University and colleagues have now made two fundamental discoveries about the so called broadly neutralizing anti-HIV antibodies, which effectively keep the virus at bay.

30 Sep 2010

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

New form of immunotherapy increases survival in children with neuroblastoma

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.

30 Sep 2010

Radical prostatectomy increases survival rate in prostate cancer patients: Study

In the largest, most modern, single-institution study of its kind, Mayo Clinic urologists mined a long-term data registry for survival rates of patients who underwent radical prostatectomy for localized prostate cancer. The findings are being presented at the North Central Section of the American Urological Association's 84th Annual Meeting in Chicago.

30 Sep 2010

Researchers develop C5 technology to identify CTCs in breast cancer

Researchers have identified a novel, dual-platform technology, the On-Q-ity Circulating Cancer Capture and Characterization Chip (C5), which they believe is more efficient than the commonly used single-platform device in identifying circulating tumor cells (CTCs) in breast cancer.

30 Sep 2010

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

30 Sep 2010

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

Breakthrough neuroblastoma treatment

According to a new study the addition of an experimental immunotherapy drug to the standard regimen of care extended the lives and decreased the risk of a disease recurrence in children with high-risk neuroblastoma. This tumor most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis. It forms 12 percent of cancer-related deaths in children under the age of 15 and half of patients with this type of malignancy have the high-risk form.

29 Sep 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its QuickVue RSV 10, a lateral flow immunoassay test for the qualitative detection of acute respiratory syncytial virus (RSV) infections.

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Morphotek announces first therapeutic monoclonal antibody for clinical development

Morphotek, Inc., a subsidiary of Eisai Inc., today announced that a monoclonal antibody has been selected for advancement to clinical development under the terms of its March 2009 collaboration agreement with Human Genome Sciences, Inc.

29 Sep 2010

National Jewish Health's liposome-based vaccine receives US patent

National Jewish Health has received a US patent for a new kind of vaccine, which uses a small lipid bubble to deliver an antigen and DNA adjuvant. Chairman of Pediatrics Erwin Gelfand, MD, and former National Jewish Health Professor of Medicine Steve Dow, PhD, developed the new liposome-based adjuvant.

29 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

Antigen News and Research

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

FDA awards $2.9 million to support tuberculosis research projects

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Healthy respect for flu this season

Discovery suggest a new direction for designing vaccines for rare HIV infection

AccuPSA test for detecting prostate cancer recurrence

New form of immunotherapy increases survival in children with neuroblastoma

Radical prostatectomy increases survival rate in prostate cancer patients: Study

Researchers develop C5 technology to identify CTCs in breast cancer

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Breakthrough neuroblastoma treatment

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Morphotek announces first therapeutic monoclonal antibody for clinical development

National Jewish Health's liposome-based vaccine receives US patent

Researchers discover new diagnostic test for prostate cancer

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News